Immunotech Laborator (IMMB) 0.0010 $IMMB
SEC Steps Up To Halt More Hype Stocks
Investor RockieK - at Seeking Alpha - Fri Nov 21, 1:14PM CST
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), PLX: 1.84 (-0.04), NLNK: 38.84 (+1.51), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
Filing Services Canada XHTML - Tue Oct 21, 7:03AM CDT
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease ("EVD"
Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
Business Wire - Tue Oct 21, 7:00AM CDT
Immunotech Laboratories, Inc. (OTC PINK: IMMB) ("Immunotech" or the "Company" and wholly-owned subsidiary Immunotech Laboratories, BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company's HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa.
Immunotech Laboratories, Inc. Enters into Negotiations with Uldic Investment Pvt. Ltd. for Market Development
Filing Services Canada XHTML - Thu Oct 09, 7:45AM CDT
Immunotech Laboratories, Inc. Enters Into Negotiations With Uldic Investment Pvt. Ltd. For Market Development
Business Wire - Thu Oct 09, 7:45AM CDT
Immunotech Laboratories, Inc. (OTCMARKETS: IMMB) Immunotech Laboratories, Inc.(the "Company" and Immunotech Laboratories, BG (IMMB-BG" the Company announced today that they have entered into negotiations with Uldic Investment Pvt. Ltd. ("Uldic" or the "Representative/Distributor" , located in Zimbabwe, to pursue the development of market opportunities and Clinical Testing for the Company's HIV/AIDS and Hepatitis C virus treatment ("ITV-1 Treatment" in Africa, initially focusing on clinical testing for Hepatitis C in Mauritius Island and Malawi.
Immunotech Laboratories, Inc. Updates Progress on Negotiations for Phase III Testing on its Treatments for HIV/AIDS and Hepatitis C Viruses in Macedonia and Serbia
Filing Services Canada XHTML - Tue Oct 07, 8:03AM CDT
Immunotech Laboratories, Inc. Announces Successful Completion of Phase I and Phase II Field Trials of the Company's Patented Treatment of the HIV/AIDS and Hepatitis C Viruses
Business Wire - Thu Aug 28, 8:00AM CDT
Immunotech Laboratories, Inc. (OTCMARKETS:IMMB) Immunotech Laboratories, Inc. announced today that the Phase I and Phase II field trials in Bulgaria of the Company's HIV/AIDS and Hepatitis C virus treatment ("ITV-1 Treatment" have been successfully completed. The clinical test are being conducted through Immunotech Laboratories, BG ("IMMB-BG" a 49% owned subsidiary of Immunotech Laboratories. Since 2013, IMMB-BG hired and funded the Clinical Research Organization ("CRO" to conduct all preclinical and monitoring Phase III clinical studies. The product for the Bulgarian study was produced under GMP conditions by a U.S. Contract Manufacturing Facility.
SEC Steps Up To Halt More Hype Stocks
Investor RockieK - at Seeking Alpha - Fri Nov 21, 1:14PM CST
SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST
BCRX: 10.06 (-0.09), VSR: 3.42 (-0.02), TKMR: 21.45 (-0.22), NNVC: 2.97 (-0.05), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), APT: 2.88 (+0.17), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), SMED: 4.75 (-0.04), PLX: 1.84 (-0.04), NLNK: 38.84 (+1.51), LAKE: 10.18 (+0.89), NSPH: 0.25 (unch)
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
Filing Services Canada XHTML - Tue Oct 21, 7:03AM CDT
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease ("EVD"
Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa Business Wire - Tue Oct 21, 7:00AM CDT
Immunotech Laboratories, Inc. (OTC PINK: IMMB) ("Immunotech" or the "Company"
and wholly-owned subsidiary Immunotech Laboratories, BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company's HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa. Immunotech Laboratories, Inc. Enters into Negotiations with Uldic Investment Pvt. Ltd. for Market Development
Filing Services Canada XHTML - Thu Oct 09, 7:45AM CDT
Immunotech Laboratories, Inc. Enters Into Negotiations With Uldic Investment Pvt. Ltd. For Market Development
Business Wire - Thu Oct 09, 7:45AM CDT
Immunotech Laboratories, Inc. (OTCMARKETS: IMMB) Immunotech Laboratories, Inc.(the "Company"
and Immunotech Laboratories, BG (IMMB-BG" the Company announced today that they have entered into negotiations with Uldic Investment Pvt. Ltd. ("Uldic" or the "Representative/Distributor" , located in Zimbabwe, to pursue the development of market opportunities and Clinical Testing for the Company's HIV/AIDS and Hepatitis C virus treatment ("ITV-1 Treatment" in Africa, initially focusing on clinical testing for Hepatitis C in Mauritius Island and Malawi. Immunotech Laboratories, Inc. Updates Progress on Negotiations for Phase III Testing on its Treatments for HIV/AIDS and Hepatitis C Viruses in Macedonia and Serbia
Filing Services Canada XHTML - Tue Oct 07, 8:03AM CDT
Immunotech Laboratories, Inc. Announces Successful Completion of Phase I and Phase II Field Trials of the Company's Patented Treatment of the HIV/AIDS and Hepatitis C Viruses
Business Wire - Thu Aug 28, 8:00AM CDT
Immunotech Laboratories, Inc. (OTCMARKETS:IMMB) Immunotech Laboratories, Inc. announced today that the Phase I and Phase II field trials in Bulgaria of the Company's HIV/AIDS and Hepatitis C virus treatment ("ITV-1 Treatment"
have been successfully completed. The clinical test are being conducted through Immunotech Laboratories, BG ("IMMB-BG" a 49% owned subsidiary of Immunotech Laboratories. Since 2013, IMMB-BG hired and funded the Clinical Research Organization ("CRO" to conduct all preclinical and monitoring Phase III clinical studies. The product for the Bulgarian study was produced under GMP conditions by a U.S. Contract Manufacturing Facility. 
